CING

Cingulate, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website cingulate.com
Employees(FY) 15
ISIN US17248W3034

Performance

+7.43%

-2.4%

-65.0%

-53.44%

-95.12%

YTD

-94.54%

Profile

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Advanced Technical Analysis

Technical Analysis of CING 2024-11-20

The stock indicators reflect a neutral sentiment, with the Moving Average Score, Oscillators Score, and Technical Score all at 56, suggesting a balanced market condition without strong bullish or bearish momentum. This indicates that investors may be in a wait-and-see mode, assessing potential catalysts for future price movements.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CING

Stock Rank

Recent News & Updates

2024-11-06 18:30
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market(Globenewswire)
2024-10-08 03:15
Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show(Globenewswire)
2024-09-11 20:30
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301(Globenewswire)
2024-08-27 04:30
Cingulate to Participate in Benzinga All Live Access Event(Globenewswire)
2024-08-23 04:45
Cingulate Announces Adjournment of Special Meeting(Globenewswire)
2024-08-14 19:45
Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD(Globenewswire)
2024-08-12 19:45
Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved(Globenewswire)
2024-07-10 19:29
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday(Investorplace)
2024-06-27 21:15
Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds(Globenewswire)
2024-06-25 04:30
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event(Globenewswire)
2024-06-24 21:20
Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance(Globenewswire)
2024-05-20 21:00
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD(Globenewswire)
2024-05-08 01:54
CING Stock Earnings: Cingulate Beats EPS for Q1 2024(Investorplace)
2024-05-07 19:00
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update(Globenewswire)
2024-04-29 17:45
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access(Globenewswire)
2024-04-28 21:00
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV(Accesswire)
2024-04-16 05:00
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024(Globenewswire)
2024-03-31 20:00
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update(Globenewswire)
2024-03-19 04:45
Cingulate to Participate in Benzinga All Live Access Event(Globenewswire)
2024-03-05 17:45
Cingulate to Attend DCAT Week 2024 in New York City(Globenewswire)
2024-02-12 17:45
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors(Globenewswire)
2024-02-06 03:15
Cingulate Announces Closing of $7.5 Million Public Offering(Globenewswire)
2024-02-01 20:15
Cingulate Announces Pricing of $7.5 Million Public Offering(Globenewswire)
2024-01-28 19:00
Longtime Cingulate Controller Jennifer Callahan Promoted to CFO(Globenewswire)
2024-01-28 17:45
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market(Globenewswire)
2023-12-27 21:15
Why Is Cingulate (CING) Stock Up 160% Today?(Investorplace)
2023-12-05 18:00
Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now(Globenewswire)
2023-12-04 18:00
Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now(Globenewswire)
2023-11-30 20:00
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)(Globenewswire)
2023-11-13 03:15
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update(Globenewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.